KRAS and neoplasm: We further employed several transgenic mouse strains and adoptive bone marrow transfer experiments to show that effective pharmacologic KRAS blockade in vivo is dependent on the presence of CCR2+ (C-C motif chemokine receptor 2) IL-1β-secreting myeloid cells in the tumor microenvironment.